ArticleCureus2026
Epigenetic Regulation and Immune Associations of TRAIL Decoy Receptors TNFRSF10C and TNFRSF10D in Glioblastoma: A Multi-omic Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Glioblastoma (GBM) is characterized by immune dysregulation and epigenetic alterations that contribute to tumor progression. Although tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling has been implicated in tumor biology, the transcriptional and immunological relevance of its decoy receptors, TNF receptor superfamily member 10C and 10D (TNFRSF10C and TNFRSF10D), in gliomas remains incompletely characterized. Methods An integrative multi-omic analysis was performed using The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Chinese Glioma Genome Atlas (CGGA) datasets in combination with Gene Expression Profiling Interactive Analysis 3 (GEPIA3), University of Alabama at Birmingham Cancer database (UALCAN), Tumor Immune Estimation Resource 3.0 (TIMER3.0), Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), and MEXPRESS platforms. Gene expression, promoter methylation, molecular subtype distribution, immune infiltration patterns, and clinical associations were evaluated using harmonized analytical workflows and cross-validation across datasets. Results Both receptors demonstrated progressive upregulation from normal brain to lower-grade glioma (LGG) and GBM, with higher expression observed in isocitrate dehydrogenase (IDH)-wildtype tumors. Promoter methylation analysis revealed inverse correlations between CpG methylation and gene expression, suggesting potential epigenetic associations. Immune deconvolution analyses showed consistent associations with myeloid cell populations, including macrophages, neutrophils, and dendritic cells (DCs), alongside limited correlations with T-cell subsets. Protein-protein interaction network analysis indicated that these receptors interact with multiple components of inflammatory and TNF/TRAIL signaling systems. Higher expression showed trends toward shorter progression-free intervals (PFI). Conclusions TNFRSF10C and TNFRSF10D demonstrate reproducible associations with methylation patterns and immune microenvironment characteristics in GBM. These findings highlight potential links between TRAIL decoy receptors and inflammatory tumor states and support further mechanistic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.